Niagen Bioscience (NAGE) Cash from Operations (2011 - 2026)
Niagen Bioscience (NAGE) reported Cash from Operations of 1194000.0 for Q1 2026, down 115.15% year-over-year from 7883000.0 in Q1 2025, and down 275.85% quarter-over-quarter from 679000.0 in Q4 2025.
Niagen Bioscience (NAGE) Cash from Operations (2011 - 2026) Analysis & Trends
Niagen Bioscience (NAGE) has 14 years of Cash from Operations data on file, last reported at 1194000.0 in Q1 2026.
- Cash from Operations for Q1 2026 came in at 1194000.0, down 115.15% year-over-year; the trailing twelve-month figure through Mar 2026 was 4427000.0 (down 77.52% YoY), and the FY2025 annual result was 13504000.0, up 11.52% from the prior year.
- Cash from Operations slipped to 1194000.0 in Q1 2026 per NAGE's latest filing, from 679000.0 in the prior quarter.
- Over five years, Cash from Operations peaked at 8583000.0 in Q4 2024 and troughed at 7198000.0 in Q1 2022.
- A 5-year average of 966941.18 and a median of 649000.0 in 2023 frame the typical range for Cash from Operations.
- The sharpest annual moves came in 2025 and 2026: Cash from Operations surged 2572.2% in 2025, then slumped 115.15% in 2026.
- A 5-year view of Cash from Operations shows it stood at 328000.0 in 2022, then soared by 297.87% to 649000.0 in 2023, then soared by 1222.5% to 8583000.0 in 2024, then tumbled by 92.09% to 679000.0 in 2025, then tumbled by 275.85% to 1194000.0 in 2026.
- Business Quant data shows NAGE's Cash from Operations at 1194000.0 in Q1 2026, 679000.0 in Q4 2025, and 3725000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Operations (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 788,338.31 Bn | 788,338.28 Bn | - | - |
| 2 | Belite Bio | 56,560.00 Bn | 56,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,329.30 Bn | 17,329.30 Bn | - | -1.67 Mn |
| 4 | Legend Biotech | 3,341.00 Bn | 3,340.71 Bn | 242.10 Mn | -12.20 Mn |
| 5 | Akari Therapeutics | 1,727.91 Bn | 1,727.91 Bn | - | -2.49 Mn |
| 6 | Evaxion A | 1,536.68 Bn | 1,536.67 Bn | - | - |
| 7 | Psyence Biomedical | 238.34 Bn | 238.33 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 113.42 Bn | 106.17 Bn | 2.59 Bn | 1.43 Bn |
| 9 | Abivax | 95.45 Bn | 95.45 Bn | - | - |
| 10 | Niagen Bioscience | 280.11 Mn | 213.56 Mn | 19.98 Mn | -1.19 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -1.19 Mn |
| Mar 31, 2026 | -1.19 Mn |
| Dec 31, 2025 | 679,000.00 |
| Dec 31, 2025 | 679,000.00 |
| Sep 30, 2025 | 3.73 Mn |
| Sep 30, 2025 | 3.73 Mn |
| Jun 30, 2025 | 1.22 Mn |
| Jun 30, 2025 | 1.22 Mn |
| Mar 31, 2025 | 7.88 Mn |
| Mar 31, 2025 | 7.88 Mn |
| Dec 31, 2024 | 8.58 Mn |
| Dec 31, 2024 | 8.58 Mn |
| Sep 30, 2024 | 3.50 Mn |
| Sep 30, 2024 | 3.50 Mn |
| Jun 30, 2024 | -264,000.00 |
| Jun 30, 2024 | -264,000.00 |
| Mar 31, 2024 | 295,000.00 |
| Mar 31, 2024 | 295,000.00 |
| Dec 31, 2023 | 649,000.00 |
| Dec 31, 2023 | 649,000.00 |